Comparative Pharmacology
Head-to-head clinical analysis: DOXIL LIPOSOMAL versus ELLENCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXIL LIPOSOMAL versus ELLENCE.
DOXIL (LIPOSOMAL) vs ELLENCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxorubicin intercalates between DNA base pairs, inhibits topoisomerase II, and generates free radicals, leading to DNA damage and cell death. Liposomal encapsulation prolongs circulation time and alters biodistribution.
ELLENCE (epirubicin) is an anthracycline cytotoxic antibiotic. It intercalates between DNA base pairs, inhibits topoisomerase II activity, and generates free radicals, leading to DNA damage and cell death.
Doxorubicin HCl liposome injection 20 mg/m2 intravenously over 1 hour every 4 weeks.
60-120 mg/m2 IV bolus or slow infusion on Day 1 every 21-28 days; or 20-30 mg/m2 IV daily for 3 days repeated every 28 days.
None Documented
None Documented
Terminal half-life is approximately 30–40 hours, prolonging drug exposure and allowing every-4-week dosing.
Terminal elimination half-life is approximately 20-40 hours (mean ~30 hours). This supports a 3-week dosing interval to allow for recovery from myelosuppression.
Primarily hepatic metabolism and biliary excretion; urinary excretion accounts for <10% of the administered dose as unchanged drug.
Primarily hepatobiliary excretion: ~40-50% of dose excreted as unchanged drug and metabolites in bile and feces. Renal excretion accounts for <10% (mostly as metabolites).
Category C
Category C
Anthracycline Antineoplastic
Anthracycline Antineoplastic